Summary

Michael Dorsch is an Assistant Professor, pharmacist and clinical researcher who studies the effects of health information technology on outcomes in cardiovascular disease. His current work focuses on increasing adherence to a low sodium diet in hypertension and increasing self-monitoring in heart failure to promote patient self-management strategies. Dr. Dorsch received his PharmD from Ohio Northern University and completed a PGY1 pharmacy practice residency at Riverside Methodist Hospital, in Columbus, Ohio, as well as a PGY2 cardiology specialty residency at University of North Carolina Hospitals, in Chapel Hill. He earned an MS in clinical research design and statistical analysis from the University of Michigan School of Public Health and an institutional K30 award from the Michigan Institue for Clinical & Health Research. Dr. Dorsch is a Board Certified Pharmacotherapy Specialist with Added Qualifications in Cardiology and named Fellow of the American College of Clinical Pharmacy and American Heart Association.

Research Interests

  • Health Information Technology

    • mHealth
    • Clinical decision support
    • Computable biomedical knowledge
  • Cardiovascular Disease Outcomes Research

    • Quality improvement
    • Health services research
  • Educational Research

    • Cirricular quality improvement
    • Team-based learning
  • If you would like to fund my research, click on the button below and add my full name where it says "Write in".

     

    UM Giving

     

     

Selected Publications

  • Lester CA, Coe AB, Dorsch MP, Farris KB, Flynn AJ. A learning pharmacy practice enabled by the pharmacists' patient care process [published online ahead of print, 2020 Jun 30]. J Am Pharm Assoc (2003). 2020;S1544-3191(20)30249-1.

  • Hanigan S, Das J, Pogue K, Barnes GD, Dorsch MP. The real world use of combined P-glycoprotein and moderate CYP3A4 inhibitors with rivaroxaban or apixaban increases bleeding. J Thromb Thrombolysis. January 2020. doi:10.1007/s11239-020-02037-3

  • Dorsch MP, Lester CA, Ding Y, Joseph M, Brook RD. Effects of Race on Statin Prescribing for Primary Prevention With High Atherosclerotic Cardiovascular Disease Risk in a Large Healthcare System. J Am Heart Assoc. 2019;8(22):e014709.

  • Adie S, Bitar A, Hanigan S, Pogue KT, Koelling TM, Dorsch MP. Real-world prevalence of adverse events after initiating sacubitril/valsartan compared to angiotensin converting enzyme inhibitors or angiotensin receptor blockers in systolic heart failure. J Card Fail. 2019 May;25(5):412-413.

  • Rollins A, Hanigan S, Pogue K, Renner E, Barnes G, Dorsch M. Identifying Clinical Predictors of Switching From Direct Oral Anticoagulants to Warfarin. Clinical Medicine Insights: Therapeutics. 2019;11:1179559X19831287.

  • Bleske BE, Remington TL, Wells TD, Klein KC, Dorsch MP. A Randomized Crossover Comparison between Team-Based Learning and Lecture Format on Long-Term Learning Outcomes. Pharmacy 2018 Aug 4;6(3). pii: E81.

  • Dorsch MP, Chong YP, McCormick MP, Grossi J, Farris KB, Koelling TM, Bleske BE. Survey of Computer, Smart Devices, and Internet use in Heart Failure Patients. International Cardiovascular Forum Journal. 2016;6:84-85.

  • Dorsch MP, Farris KB, Bleske BE, Koelling TM. A web application for self-monitoring improves symptoms in chronic systolic heart failure. Telemed J E Health. 2015;21(4):267-70.

  • Bleske BE, Dillman NO, Cornelius D, Ward JK, Burson SC, Diez HL, Pickworth KK, Bennett MS, Nicklas JM, Dorsch MP. Heart failure assessment at the community pharmacy level: a feasibility pilot study. J Am Pharm Assoc. 2014 Nov-Dec;54(6):634-41.

  • Dorsch MP, Gillespie BW, Erickson SR, Bleske BE, Weder AB. Chlorthalidone reduces cardiovascular events compared to hydrochlorothiazide: A retrospective cohort analysis. Hypertension 2011 Apr;57(4):689-94.

  •  

    Full List of Publications